Discontinuation report ERWINASE
| Report ID | 129623 |
| Drug Identification Number | 02237815 |
| Brand name | ERWINASE |
| Common or Proper name | Erwinia L-asparaginase |
| Company Name | JAZZ PHARMACEUTICALS FRANCE SAS |
| Market Status | MARKETED |
| Active Ingredient(s) | ASPARAGINASE |
| Strength(s) | 10000UNIT |
| Dosage form(s) | POWDER FOR SOLUTION |
| Route of administration | INTRAMUSCULAR INTRAVENOUS SUBCUTANEOUS INTRAMUSCULAR INTRAVENOUS SUBCUTANEOUS |
| Packaging size | 3 mL vials |
| ATC code | L01XX |
| ATC description | OTHER ANTINEOPLASTIC AGENTS |
| Reason for discontinuation | Business reasons |
| Anticipated discontinuation date | 2021-04-01 |
| Actual discontinuation date | |
| Remaining supply date | 2021-02-28 |
| Discontinuation status | To be discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | Lot 205H121 is out of stock. Supply of lot 205H121 has been prioritized for existing patients. |
| Company comments | Distribution of Erwinase by Jazz Pharmaceuticals will end now that lot 205H121 (“CAMR205”) is exhausted. For all enquiries about future supply beyond Lot 205H121, please contact Clinigen at https://www.clinigengroup.com/direct/en-gb/products/detail/erwinia-l-asparaginase |
| Health Canada comments | |
| Contact Address | 84 QUAI CHARLES DE GAULLE CITY ONE LYON, AUVERGNE-RHONE-ALPES FRANCE 69006 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v9 | 2021-03-31 | French | Compare |
| v8 | 2021-03-31 | English | Compare |
| v7 | 2021-03-31 | English | Compare |
| v6 | 2021-03-31 | English | Compare |
| v5 | 2020-12-11 | French | Compare |
| v4 | 2020-12-11 | English | Compare |
| v3 | 2020-12-04 | French | Compare |
| v2 | 2020-12-04 | English | Compare |
| v1 | 2020-12-04 | English | Compare |